Pittsburgh Life Sciences Greenhouse

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company specializes in developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. By enabling pre-hospital providers to accurately assess patients, AlphaStroke facilitates timely triage and enhances decision-making in critical care scenarios, ultimately aiming to reduce treatment delays and improve patient outcomes.

Neuro Kinetics, Inc. is a medical technology company based in Pittsburgh, Pennsylvania, specializing in eye tracking technology and non-invasive neuro-otologic diagnostic testing tools. Founded in 1984, the company serves a global clientele of audiologists, ENT specialists, neuro-otologists, neuro-ophthalmologists, and neurologists. Its product portfolio includes the I-PORTAL Neuro-Otologic Test Center, which provides a comprehensive vestibular testing solution, along with various software and diagnostic tools such as VEST for neuro-otologic analysis, Video Nystagmography, and Video Oculography for vestibular assessments. Neuro Kinetics also offers training, maintenance, and support services to enhance the use of its products. By providing tools for the evaluation of neurologic, otologic, and vestibular disorders, Neuro Kinetics enables healthcare professionals to initiate treatment more promptly, thereby improving the chances of successful outcomes for patients.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Ariel Precision Medicine, Inc. is an integrated genomics and digital health company focused on providing precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases and disorders. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, the company develops innovative clinical decision support tools aimed at simplifying personalized treatment in both emergency departments and clinical settings. One of its key offerings is ArielDx, a cloud-based tool designed to enhance the diagnosis and treatment of pancreatic disease, thereby improving patient outcomes through tailored healthcare solutions.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company specializes in developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. By enabling pre-hospital providers to accurately assess patients, AlphaStroke facilitates timely triage and enhances decision-making in critical care scenarios, ultimately aiming to reduce treatment delays and improve patient outcomes.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

ALung Technologies, Inc., established in 1997 and based in Pittsburgh, Pennsylvania, specializes in developing and manufacturing medical devices for treating acute respiratory failure. The company's primary product is the Hemolung Respiratory Assist System, a dialysis-like device that removes carbon dioxide and delivers oxygen directly to the blood, allowing patients' lungs to rest and heal while avoiding intubation and facilitating protective ventilation.

ATRP SOLUTIONS develops and manufactures specialty polymers that meet their needs. It recognizes the polymeric materials for improving the performance of commercial products in the areas of personal care and cosmetics, detergents and surfactants, paints, pigments, coatings, and biocompatible materials. It was founded in 2006 and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

STARR Life Sciences Corp. specializes in developing and manufacturing equipment for small animal research, catering to the needs of life science laboratories globally. Founded in 2004 and based in Oakmont, Pennsylvania, the company offers a diverse range of products designed specifically for mice, rats, and other small animals. Key offerings include the MouseOX Plus, a pulse oximeter that measures vital signs such as heart rate and arterial oxygen saturation, and the E-Mitter Telemetry System, which allows continuous monitoring of temperature, motor activity, and heart rate. Additionally, STARR Life Sciences provides various sensors, software modules, and activity monitoring systems that enable researchers and veterinarians to track the health and behavior of their subjects without causing disruption. Their products are utilized by universities, pharmaceutical companies, and contract research organizations, reflecting the company’s commitment to advancing medical research through innovative solutions.

NeuroInterventional Therapeutics, Inc. ("NIT", dba Neurointerventions, Inc.) is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus ("blood clots") in a wide range of cerebral vessels, thereby increasing chances of survival and minimizing disability.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, focused on developing and commercializing diagnostic blood tests that enhance personalized medicine. The company offers a range of products aimed at optimizing drug therapy in psychiatry and oncology. Its MyCare product line includes tests such as MyCare Psychiatry, which helps determine appropriate antipsychotic dosages; MyCare Oncology, which focuses on chemotherapy exposure optimization; and MyCare Neurology for assessing neurological drug effects. Key tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are designed to tailor chemotherapy treatments for various cancers. Saladax Biomedical markets its diagnostic solutions to healthcare providers worldwide through both distributors and direct sales, striving to empower physicians to deliver personalized care by ensuring optimal drug dosing. The company has been providing innovative diagnostic solutions for over 15 years.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Caliber Infosolutions, Inc. is a Pittsburgh-based company specializing in web-based software applications tailored for regulated industries, particularly in quality management for the pharmaceutical and biotechnology sectors. The company's flagship product, CaliberLIMS, automates batch, lot, and sample management, ensuring compliance with manufacturing specifications. Additionally, Caliber Stability facilitates the pre-registration of stability test protocols and provides statistical analyses of test results, while Caliber Pet-LIMS offers customizable laboratory information management solutions, including various reporting tools. Caliber also features Caliber CLAPS, a controlled label printing system designed for regulated environments. Alongside its software offerings, the company provides validation, implementation, training, and customer support services. Established in 2008, Caliber Infosolutions has formed strategic partnerships with industry leaders, enhancing its capabilities and reach within the biotech, pharmaceutical, oil, and petrochemical industries.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, focused on developing and commercializing diagnostic blood tests that enhance personalized medicine. The company offers a range of products aimed at optimizing drug therapy in psychiatry and oncology. Its MyCare product line includes tests such as MyCare Psychiatry, which helps determine appropriate antipsychotic dosages; MyCare Oncology, which focuses on chemotherapy exposure optimization; and MyCare Neurology for assessing neurological drug effects. Key tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are designed to tailor chemotherapy treatments for various cancers. Saladax Biomedical markets its diagnostic solutions to healthcare providers worldwide through both distributors and direct sales, striving to empower physicians to deliver personalized care by ensuring optimal drug dosing. The company has been providing innovative diagnostic solutions for over 15 years.

Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing intravesical therapies and reformulations of existing drugs to treat bladder diseases. The company aims to deliver local treatments directly to the urinary bladder lumen, targeting conditions such as hemorrhagic cystitis, interstitial cystitis, overactive bladder, and superficial bladder cancer. Its product candidates include LP-10, a liposomal tacrolimus formulation for hemorrhagic cystitis, and additional agents such as LP-310 and LP-410 for related urological indications. By pursuing bladder-directed delivery, Lipella seeks to provide targeted therapy with reduced systemic exposure. The company traces its origins to 2005 and is based in Pittsburgh, Pennsylvania, and it also provides surveillance and imaging for patients with a history of transitional cell carcinoma, alongside clinical supplies and research products supporting its development efforts.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company aims to restore normal cellular damage responses by targeting toxic proteins that contribute to cognitive decline, particularly in conditions such as Alzheimer's disease and dry age-related macular degeneration. Its lead product candidate, CT1812, is an orally administered drug designed to penetrate the blood-brain barrier and selectively bind to the S2R complex. Through its expertise in biological research and proprietary medicinal chemistry, Cognition Therapeutics is dedicated to creating innovative drug candidates that address significant unmet medical needs in the treatment of degenerative diseases.

Founded in 2004, Crystalplex specializes in the development and manufacturing of robust Quantum Dots for various applications. Their proprietary Sapphire™ QDs offer stable crystal design and flexible polymer matrix morphology, enabling enhanced performance in biomedical research, molecular diagnostics, pathology, photoluminescent displays, and solar energy technologies.

Founded in 2003, Applied Isotope Technologies specializes in providing high-precision measurement solutions for various industries. It offers direct isotope dilution mass spectrometry (D-IDMS) and speciated isotope dilution mass spectrometry (D-SIDMS) technologies, along with QA certification, training, and isotopically labeled products. The company's services cater to environmental toxin detection, biomarker measuring, fossil fuel testing, food safety analysis, and more.

Separation Design Group, LLC is a research and product development firm based in Waynesburg, Pennsylvania, founded in 2003. The company specializes in the design and manufacture of miniature oxygen generators for a variety of applications, including wound care, respiratory disease management, organ transplantation, and veterinary care. Its innovative technologies include portable medical oxygen concentrators, oxygen therapy devices, and oxygen generation modules for ozone generation. Additionally, the company develops solutions for personal and sports oxygen use and hybrid fuel electric aircraft engines. With research facilities located in Pittsburgh, Pennsylvania, and Morgantown, West Virginia, Separation Design Group focuses on creating energy-efficient equipment that operates at faster cycle times, thereby enhancing performance across industrial, medical, and commercial sectors.

Founded in 2005, InteloMed specializes in medical device technology for non-invasive, real-time monitoring of the cardiovascular system. Its flagship product, CVInsight Patient Monitoring & Informatics System, captures and processes a patient’s pulse waveform using proprietary algorithms, serving hospitals, medical facilities, and ambulatory care settings.

ChemDAQ, Inc. is a manufacturer of gas detection systems designed to protect personnel from exposure to toxic sterilant gases. Founded in 1996 and based in Pittsburgh, Pennsylvania, the company provides solutions such as the ChemDAQ sterilant gas monitoring system and the ChemDAQ data acquisition module. These systems enable continuous monitoring, data recording, and documentation of sterilant gas levels, ensuring safety in various environments. ChemDAQ primarily serves hospitals and organizations within the healthcare, medical device manufacturing, and food and beverage industries, helping them maintain a safe and productive work environment.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

STARR Life Sciences Corp. specializes in developing and manufacturing equipment for small animal research, catering to the needs of life science laboratories globally. Founded in 2004 and based in Oakmont, Pennsylvania, the company offers a diverse range of products designed specifically for mice, rats, and other small animals. Key offerings include the MouseOX Plus, a pulse oximeter that measures vital signs such as heart rate and arterial oxygen saturation, and the E-Mitter Telemetry System, which allows continuous monitoring of temperature, motor activity, and heart rate. Additionally, STARR Life Sciences provides various sensors, software modules, and activity monitoring systems that enable researchers and veterinarians to track the health and behavior of their subjects without causing disruption. Their products are utilized by universities, pharmaceutical companies, and contract research organizations, reflecting the company’s commitment to advancing medical research through innovative solutions.

Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing intravesical therapies and reformulations of existing drugs to treat bladder diseases. The company aims to deliver local treatments directly to the urinary bladder lumen, targeting conditions such as hemorrhagic cystitis, interstitial cystitis, overactive bladder, and superficial bladder cancer. Its product candidates include LP-10, a liposomal tacrolimus formulation for hemorrhagic cystitis, and additional agents such as LP-310 and LP-410 for related urological indications. By pursuing bladder-directed delivery, Lipella seeks to provide targeted therapy with reduced systemic exposure. The company traces its origins to 2005 and is based in Pittsburgh, Pennsylvania, and it also provides surveillance and imaging for patients with a history of transitional cell carcinoma, alongside clinical supplies and research products supporting its development efforts.

RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, specializing in oncology support services. Founded in 2004, the company operates a diagnostic platform known as PathFinderTG, which focuses on the early and definitive diagnosis of cancer. This platform utilizes advanced techniques to analyze genetic mutations, extracting objective and quantitative genetic information from small tissue biopsies, cytology samples, and fluid specimens. By providing these insights, RedPath aids pathologists, clinicians, and patients in resolving complex diagnostic challenges, particularly in cases where cancer treatments do not produce expected results.

Immunetrics, Inc. is a biosimulation company based in Pittsburgh, Pennsylvania, established in 2003. It specializes in developing biological models and innovative tools for mechanistic modeling, particularly in the context of drug discovery and development. The company offers a software platform called Aegis, designed for model developers, along with disease-specific models and component model libraries. Its modeling software facilitates the creation of models, virtual populations, and experiments, enabling in-depth analysis of human diseases and syndromes. Additionally, Immunetrics provides consulting services in mechanistic and statistical modeling, as well as data analysis, aimed at predicting clinical outcomes of therapeutic interventions for various inflammatory and autoimmune diseases at both individual and trial population levels.

Proteopure offers protein isolation solutions for proteomic results. The company provides a universal method for isolating proteins. Its sample preparation kit uses a protein capture technology, and can specifically separate out proteins from various contaminants, including salts, nucleic acids, and detergents. Proteopure is headquartered in Pittsburgh, Pennsylvania.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Founded in 2003, Applied Isotope Technologies specializes in providing high-precision measurement solutions for various industries. It offers direct isotope dilution mass spectrometry (D-IDMS) and speciated isotope dilution mass spectrometry (D-SIDMS) technologies, along with QA certification, training, and isotopically labeled products. The company's services cater to environmental toxin detection, biomarker measuring, fossil fuel testing, food safety analysis, and more.